Current pharmacotherapy of overactive bladder

Kreydin, Evgeniy; Gomes, Cristiano Mendes; Cruz, Francisco

doi:10.1590/s1677-5538.ibju.2021.99.12

Cited by 18 publications

(28 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmacotherapy of OAB relies essentially on the use of two β 3 -adrenergic agonists: vibegron ( Gemtesa ® , FDA-approved in 2020) and mirabegron ( Myrbetriq ® , FDA-approved in 2012) with a comparable limited efficacy, even if vibegron, with less side effect on blood pressure, is often preferred to mirabegron [ 5 , 6 , 7 , 8 ]. A few other options are available, including the use of botulinum toxin A, neuromodulation with implantable devices, and laser treatment but their efficacy is limited [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Sauzeau

Beignet²,

Bailly

2022

Biomedicines

View full text Add to dashboard Cite

Bladder pathologies, very common in the aged population, have a considerable negative impact on quality of life. Novel targets are needed to design drugs and combinations to treat diseases such as overactive bladder and bladder cancers. A promising new target is the ubiquitous Rho GTPase Rac1, frequently dysregulated and overexpressed in bladder pathologies. We have analyzed the roles of Rac1 in different bladder pathologies, including bacterial infections, diabetes-induced bladder dysfunctions and bladder cancers. The contribution of the Rac1 protein to tumorigenesis, tumor progression, epithelial-mesenchymal transition of bladder cancer cells and their metastasis has been analyzed. Small molecules selectively targeting Rac1 have been discovered or designed, and two of them—NSC23766 and EHT 1864—have revealed activities against bladder cancer. Their mode of interaction with Rac1, at the GTP binding site or the guanine nucleotide exchange factors (GEF) interaction site, is discussed. Our analysis underlines the possibility of targeting Rac1 with small molecules with the objective to combat bladder dysfunctions and to reduce lower urinary tract symptoms. Finally, the interest of a Rac1 inhibitor to treat advanced chemoresistance prostate cancer, while reducing the risk of associated bladder dysfunction, is discussed. There is hope for a better management of bladder pathologies via Rac1-targeted approaches.

show abstract

Section: Introductionmentioning

confidence: 99%

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Sauzeau

Beignet²,

Bailly

2022

Biomedicines

View full text Add to dashboard Cite

show abstract

“…However, the findings of the present study contradict the aforementioned research. Age is a well-known risk factor [ 40 – 42 ]. Studies conducted by Donaldson MM and Lightner DJ that the prevalence of OAB increases with age; however, aging does not seem to be considered one of the primary risk factors for OAB in Chinese women in our study [ 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of overactive bladder in Chinese women: A systematic review and meta-analysis

Huang,

Guo,

Tai

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Overactive bladder (OAB) is a significant public health issue that adversely affects the quality of life of patients and imposes a significant socioeconomic burden, with varying prevalence rates across study populations in Chinese women. A systematic review and meta-analysis were conducted to estimate the prevalence of OAB in Chinese women. Methods Relevant published articles on the prevalence of OAB in Chinese women were searched through July 21, 2022, using PubMed, EMbase, The Cochrane Library, China Biology Medicine (CBM), China National Knowledge Infrastructure (CNKI), WanFang Data, and VIP databases. After the independent screening of articles, data extraction, and quality assessment of included studies by two investigators, a meta-analysis was performed using Stata 16.0 software, and the prevalence was determined using a random-effects model. To identify potential sources of heterogeneity, subgroup analyses were conducted with subgroup categories including age, Body Mass Index (BMI), region, and survey year. Publication bias was assessed by visually examining the funnel plot and Egger’s test. Results Twenty studies were included in this meta-analysis. The results of the random-effects model indicated that the prevalence of OAB in Chinese women was 14% (95% Confidence Interval: 9%–18%). The prevalence increased significantly in the past decade (from 8% in pre-2006 to 18% in 2016–2021). A prevalence (18%) was observed among women aged 31–40 compared with other age groups. The BMI range of 24–27.9 (18%) was higher than the other groups. Additionally, the prevalence of this BMI range was comparatively higher in North China and Southwest China (21%) than in Central China and East China. In addition, publication bias was observed. Conclusions OAB incidence has increased in Chinese women over the last two decades, affecting more than 20% of women aged 31–40 years and above. With the increasing prevalence of OAB, greater emphasis has been placed on implementing preventative and control measures.

show abstract

“…In the absence of other (e.g. neurological) diseases, overactive bladder is a symptom complex comprising of uncomfortable stored urine symptoms such as urinary frequency, urgency, and nocturia (2). The main diagnostic tools for overactive bladder (OAB) are a detailed history, physical exam, urinalysis (to rule out infection and microscopic hematuria), a post--void residual measured by ultrasound, and a frequency-volume chart (which can highlight fluid intake, average and maximum bladder volumes, and timing of voids).…”

Section: Introductionmentioning

confidence: 99%

“…The main diagnostic tools for overactive bladder (OAB) are a detailed history, physical exam, urinalysis (to rule out infection and microscopic hematuria), a post--void residual measured by ultrasound, and a frequency-volume chart (which can highlight fluid intake, average and maximum bladder volumes, and timing of voids). When the diagnosis is unknown or there is a high suspicion for another ailment, more advanced diagnostic modalities such as urodynamics, cystoscopy, or upper tract imaging are required (1,2). However, daytime symptoms may overlap between conditions such as an OAB or non-monosymptomatic nocturnal enuresis accompanied by urinary frequency and nocturia with or without urinary incontinence (3).…”

Section: Introductionmentioning

confidence: 99%

Could urinary nerve growth factor and bladder wall thickness predict the treatment outcome of children with overactive bladder?

et al. 2022

View full text Add to dashboard Cite

Objective: Bladder wall thickness (BWTh) measurements and Nerve Growth Factor (NGF) /creatinine (Cr) values, as noninvasive tools, were found to predict daytime voiding problems in children with overactive bladder (OAB). The goal of this research was to examine if bladder wall thickness together with urine NGF/Cr could be a clinical utility in treatment outcome of OAB in children. Patients and Methods: A total of 60 children with OAB, (Group 1; n=40) and healthy normal controls (Group 2; n=20), aged 6-14 years old were involved in this prospective study. Children were evaluated with detailed history and physical examination, including neurologic examination, and were asked to complete a self-reported questionnaire and a 3-day bladder diary with the aid of their parents. Urofl owmetry was performed in all cases. Urinary nerve growth factor levels were measured by the ELISA and BWTh was measured trans-abdominally by one uro-radiologist specialized in pediatric ultrasonography. Urinary NGF levels were normalized by urinary creatinine levels and compared among all subgroups. Children with OAB received urotherapy as fi rst line treatment at least for three months. 18 children refractory to urotherapy received anticholinergic therapy defi ned as group 3. Results: The median age of the study group was 10 (range 6 to 16). After urotherapy, 22 children had similar BWTh and NGF/Cr values compared to controls. (2.75 ± 1.15; 2.40 ± 1.00 mm; p=0.86 and 1.02 ± 0.10; 0.78 ± 0.15; p=0.12, respectively). After anticholinergic treatment, BWTh levels (2.25 ± 0.90; 2.40 ± 1.00 mm; p=0.94) and NGF/Cr values (0.95 ± 0.10; 0.78 ± 0.15; p=0.42, respectively) had no signifi cantly difference compared to controls (Group 2). In receiver operating characteristic analysis, bladder wall thickness was found to have sensitivity of 85% and specifi city of 84.2% (3,20 AUC ,913; 95 %) and NGF/Cr had sensitivity of 90% and specifi city of 92.1% (1,595; AUC ,947; 95 %) in predicting treatment outcome in children with OAB. Conclusions: Bladder wall thickness measurements and NGF/Cr values, as noninvasive tools, could guide outcomes in the treatment of children with overactive bladder.

show abstract

Current pharmacotherapy of overactive bladder

Cited by 18 publications

References 120 publications

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Prevalence of overactive bladder in Chinese women: A systematic review and meta-analysis

Could urinary nerve growth factor and bladder wall thickness predict the treatment outcome of children with overactive bladder?

Contact Info

Product

Resources

About